Bayer's (OTC: BAYRY) new cancer drug, Vitraki, was formally rejected by health care watchdogs in both England and Germany. On Friday, the National Institute for Health and Care Excellence (NICE), a leading English health regulator, announced that it could not approve the drug at its current price tag and said it was simply not cost-effective.
In draft guidelines released Friday, England's National Institute f....
Tags : Market Research Report, Industry Research Report, Business Research report, Market Size, Market survey, intelligence Reports,
comments (0)